300 related articles for article (PubMed ID: 35385102)
1. Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.
Macaluso FS; Giuliano A; Fries W; Viola A; Abbruzzese A; Cappello M; Giuffrida E; Carrozza L; Privitera AC; Magnano A; Ferracane C; Scalisi G; Minissale MG; Giangreco E; Garufi S; Bertolami C; Cucinotta U; Graziano F; Casà A; Renna S; Teresi G; Rizzuto G; Mannino M; Maida M; Orlando A
Inflamm Bowel Dis; 2023 Feb; 29(2):217-221. PubMed ID: 35385102
[TBL] [Abstract][Full Text] [Related]
2. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.
Brenner EJ; Ungaro RC; Gearry RB; Kaplan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Ruemmele FM; Steinwurz F; Underwood FE; Zhang X; Colombel JF; Kappelman MD
Gastroenterology; 2020 Aug; 159(2):481-491.e3. PubMed ID: 32425234
[TBL] [Abstract][Full Text] [Related]
3. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.
Classen JM; Muzalyova A; Nagl S; Fleischmann C; Ebigbo A; Römmele C; Messmann H; Schnoy E
Dig Dis; 2022; 40(6):719-727. PubMed ID: 34915480
[TBL] [Abstract][Full Text] [Related]
4. Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock.
D'Amico F; Danese S; Peyrin-Biroulet L
Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2689-2700. PubMed ID: 32777550
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves.
Bezzio C; Vernero M; Costa S; Armuzzi A; Fiorino G; Ardizzone S; Roselli J; Carparelli S; Orlando A; Caprioli FA; Castiglione F; Viganò C; Ribaldone DG; Zingone F; Monterubbianesi R; Imperatore N; Festa S; Daperno M; Scucchi L; Ferronato A; Pastorelli L; Alimenti E; Balestrieri P; Ricci C; Cappello M; Felice C; Coppini F; Alvisi P; Di Luna I; Gerardi V; Variola A; Mazzuoli S; Lenti MV; Saibeni S;
BMC Gastroenterol; 2023 Jul; 23(1):230. PubMed ID: 37407913
[TBL] [Abstract][Full Text] [Related]
6. Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection?
Macedo Silva V; Lima Capela T; Freitas M; Cúrdia Gonçalves T; Boal Carvalho P; Dias de Castro F; João Moreira M; Cotter J
Inflamm Bowel Dis; 2023 Feb; 29(2):268-273. PubMed ID: 36099059
[TBL] [Abstract][Full Text] [Related]
7. Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease.
Scucchi L; Neri B; Sarmati L; Mossa M; Sena G; Massoud R; Petruzziello C; Musumeci M; Marafini I; Calabrese E; Lolli E; Bernardini S; Andreoni M; Monteleone G; Biancone L
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2418-2424. PubMed ID: 33755981
[TBL] [Abstract][Full Text] [Related]
8. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID.
Weaver KN; Zhang X; Dai X; Watkins R; Adler J; Dubinsky MC; Kastl A; Bousvaros A; Strople JA; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda E; Farraye FA; Boccieri ME; Firestine A; Kappelman MD; Long MD
Inflamm Bowel Dis; 2022 Oct; 28(10):1497-1505. PubMed ID: 34871388
[TBL] [Abstract][Full Text] [Related]
9. Possible Impact of Vitamin D Status and Supplementation on SARS-CoV-2 Infection Risk and COVID-19 Symptoms in a Cohort of Patients with Inflammatory Bowel Disease.
De Nicolò A; Cusato J; Bezzio C; Saibeni S; Vernero M; Disabato M; Caviglia GP; Ianniello A; Manca A; D'Avolio A; Ribaldone DG
Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615826
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases.
Burke KE; Kochar B; Allegretti JR; Winter RW; Lochhead P; Khalili H; Colizzo FP; Hamilton MJ; Chan WW; Ananthakrishnan AN
Inflamm Bowel Dis; 2021 Jan; 27(2):155-161. PubMed ID: 33089863
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic.
Lin S; Lau LH; Chanchlani N; Kennedy NA; Ng SC
Gut; 2022 Jul; 71(7):1426-1439. PubMed ID: 35477864
[TBL] [Abstract][Full Text] [Related]
12. Expert Opinions on the Current Therapeutic Management of Inflammatory Bowel Disease during the COVID-19 Pandemic: Japan IBD COVID-19 Taskforce, Intractable Diseases, the Health and Labor Sciences Research.
Nakase H; Matsumoto T; Matsuura M; Iijima H; Matsuoka K; Ohmiya N; Ishihara S; Hirai F; Wagatsuma K; Yokoyama Y; Hisamatsu T
Digestion; 2021; 102(5):814-822. PubMed ID: 32892197
[TBL] [Abstract][Full Text] [Related]
13. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
Bezzio C; Armuzzi A; Furfaro F; Ardizzone S; Milla M; Carparelli S; Orlando A; Caprioli FA; Castiglione F; Viganò C; Ribaldone DG; Zingone F; Monterubbianesi R; Imperatore N; Festa S; Daperno M; Scucchi L; Ferronato A; Pastorelli L; Balestrieri P; Ricci C; Cappello M; Felice C; Fiorino G; Saibeni S;
Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1432-1441. PubMed ID: 34694009
[TBL] [Abstract][Full Text] [Related]
14. High seroprevalence against SARS-CoV-2 in non-vaccinated patients with inflammatory bowel disease from Northern India.
Kante B; Vuyyuru SK; Gupta R; Dwivedi T; Kumar P; Mundhra S; Golla R; Virmani S; Verma M; Makharia G; Ahuja V; Kedia S
Indian J Gastroenterol; 2023 Feb; 42(1):70-78. PubMed ID: 36738383
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study.
Bezzio C; Saibeni S; Variola A; Allocca M; Massari A; Gerardi V; Casini V; Ricci C; Zingone F; Amato A; Caprioli F; Lenti MV; Viganò C; Ascolani M; Bossa F; Castiglione F; Cortelezzi C; Grossi L; Milla M; Morganti D; Pastorelli L; Ribaldone DG; Sartini A; Soriano A; Manes G; Danese S; Fantini MC; Armuzzi A; Daperno M; Fiorino G;
Gut; 2020 Jul; 69(7):1213-1217. PubMed ID: 32354990
[TBL] [Abstract][Full Text] [Related]
16. Risk of adverse outcomes in inflammatory bowel disease patients infected with SARS-CoV-2: a systematic review and meta-analysis.
Chen L; Hu K; Cheng C; Hu Q; Zhang L; An T; Guo Y; Chen S; Duan G
Int J Colorectal Dis; 2022 Nov; 37(11):2277-2289. PubMed ID: 36271206
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 outcomes in patients with inflammatory bowel diseases in Latin America: Results from SECURE-IBD registry.
Queiroz NSF; Martins CA; Quaresma AB; Hino AAF; Steinwurz F; Ungaro RC; Kotze PG
J Gastroenterol Hepatol; 2021 Nov; 36(11):3033-3040. PubMed ID: 34151470
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 Igg seroprevalence in IBD patients treated with biologics: first vs. second pandemic wave in a prospective study.
Mossa M; Neri B; Montesano L; Salvatori S; Marafini I; Scucchi L; Lolli E; Massoud R; Petruzziello C; Bernardini S; Calabrese E; Monteleone G; Biancone L
Eur Rev Med Pharmacol Sci; 2022 May; 26(10):3787-3796. PubMed ID: 35647861
[TBL] [Abstract][Full Text] [Related]
19. Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic.
El Ouali S; Rubin DT; Cohen BL; Regueiro MD; Rieder F
Curr Opin Gastroenterol; 2021 Jul; 37(4):313-319. PubMed ID: 33859104
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory bowel disease and risk of severe COVID-19: A nationwide population-based cohort study in Sweden.
Ludvigsson JF; Axelrad J; Halfvarson J; Khalili H; Larsson E; Lochhead P; Roelstraete B; Simon TG; Söderling J; Olén O
United European Gastroenterol J; 2021 Mar; 9(2):177-192. PubMed ID: 33704918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]